PI3 kinase as a therapeutic target for diseases associated with mutations in the catalytic domain of Kit.

被引：0
|
作者：
Linnekin, D [1 ]
Krupa, S [1 ]
机构：
[1] NCI, Frederick Canc Res Facil, Basic Res Lab, Frederick, MD USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
712
引用
收藏
页码：190A / 190A
页数：1
相关论文
共 50 条
  • [41] GATOR1 Mutations Impair PI3 Kinase-Dependent Growth Factor Signaling Regulation of mTORC1
    Muller, Maeline
    Belanger, Jasmine
    Hadj-Aissa, Imane
    Zhang, Conghao
    Sephton, Chantelle F.
    Dutchak, Paul A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
  • [42] An oncogenic c-Kit mutant induces factor-independent growth via PI3 kinase and Jnk-dependent pathways.
    Krupa, S
    Watering, N
    Linnekin, D
    BLOOD, 2001, 98 (11) : 76A - 76A
  • [43] Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
    Colamonici, Marco
    Blyth, Gavin
    Saleiro, Diana
    Szilard, Amy
    Bliss-Moreau, Meghan
    Giles, Francis J.
    Altman, Jessica K.
    Beauchamp, Elspeth M.
    Platanias, Leonidas C.
    ONCOTARGET, 2015, 6 (10) : 8062 - 8070
  • [44] Visfatin Upregulates eNOS and Improves Endothelial Cell Function and Angiogenesis via the PI3 Kinase/Akt Pathway: A Novel Vasculoprotective Target
    Lovren, Fina
    Pan, Yi
    Seth, Rishie
    Shukla, Praphulla C.
    Quan, Adrian
    Teoh, Hwee
    Peterson, Mark D.
    Al-Omran, Mohammed
    Errett, Lee
    Verma, Subodh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) : A432 - A432
  • [45] PI-3 kinase p110 beta: a therapeutic target in advanced prostate cancers
    Li, Benyi
    Sun, Aijing
    Jiang, Wencong
    Thrasher, J. Brantley
    Terranova, Paul
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2014, 2 (03): : 188 - 198
  • [46] Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
    Mirzoeva, Olga K.
    Collisson, Eric A.
    Schaefer, Peter M.
    Hann, Byron
    Hom, Yun K.
    Ko, Andrew H.
    Korn, W. Michael
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (10) : 2213 - 2225
  • [47] Interleukin (IL)-7 activates PI3 kinase pathway and inactivates Bad both of which are associated with T cell survival
    Li, WQ
    Jiang, Q
    Khaled, A
    Durum, S
    FASEB JOURNAL, 2003, 17 (07): : C294 - C294
  • [48] NVP-BEZ235 a dual inhibitor of phosphatidylinositol 3-Kinase (PI3 Kinase) and mammalian target of rapamycin (mTOR) potently enhances the effects of ionizing radiation.
    Solomon, Benjamin
    Natoli, Anthony
    Hagekyriakou, Jim
    Cullinane, Carleen
    McArthur, Grant
    CANCER RESEARCH, 2009, 69
  • [49] The PI3K/mTOR pathway is a potential therapeutic target in cancers with ARID1A mutations
    Kwan, Suet-Yan
    Izaguirre, Daisy I.
    Cheng, Xuanjin
    Kwan, Suet-Ying
    Tsang, Yvonne T. M.
    Kwan, Hoi-Shan
    Wong, Kwong-Kwok
    CANCER RESEARCH, 2015, 75
  • [50] PI3 kinase/Akt/HIF-1α pathway is associated with hypoxia-induced EMT in fibroblast-like synoviocytes
    Guo, Shi-Yu
    Li, Guo-Qing
    Liu, Yan-Qing
    Fukushima, Masaya
    Kitamura, Atsuko
    Sunagawa, Masataka
    Hisamitsu, Tadashi
    JOURNAL OF PHYSIOLOGICAL SCIENCES, 2013, 63 : S148 - S148
12345